Centessa Pharmaceuticals (NASDAQ:CNTA) Given Buy Rating at Chardan Capital

Chardan Capital reiterated their buy rating on shares of Centessa Pharmaceuticals (NASDAQ:CNTA) in a research note released on Friday,Benzinga reports. The brokerage currently has a $30.00 target price on the stock.

Other research analysts have also issued reports about the stock. B. Riley lifted their price objective on shares of Centessa Pharmaceuticals from $33.00 to $42.00 and gave the company a “buy” rating in a research note on Monday, December 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, October 8th. Stephens assumed coverage on Centessa Pharmaceuticals in a research note on Tuesday, October 28th. They set an “overweight” rating and a $35.00 price objective for the company. Wells Fargo & Company increased their price objective on Centessa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “overweight” rating in a research report on Thursday, November 13th. Finally, Wall Street Zen raised Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, October 27th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Centessa Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $37.70.

Centessa Pharmaceuticals Stock Down 5.3%

CNTA opened at $23.69 on Friday. The business’s 50-day simple moving average is $26.23 and its 200-day simple moving average is $21.00. The stock has a market capitalization of $3.18 billion, a P/E ratio of -12.95 and a beta of 1.56. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.57 and a current ratio of 10.56. Centessa Pharmaceuticals has a one year low of $9.60 and a one year high of $30.58.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). Analysts anticipate that Centessa Pharmaceuticals will post -1.6 EPS for the current year.

Insider Buying and Selling at Centessa Pharmaceuticals

In related news, CTO Tia L. Bush sold 40,000 shares of Centessa Pharmaceuticals stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $26.00, for a total transaction of $1,040,000.00. Following the completion of the sale, the chief technology officer owned 121,503 shares in the company, valued at approximately $3,159,078. This trade represents a 24.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Mario Alberto Accardi sold 10,000 shares of Centessa Pharmaceuticals stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $30.00, for a total transaction of $300,000.00. Following the sale, the insider owned 178,801 shares of the company’s stock, valued at approximately $5,364,030. This trade represents a 5.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 64,000 shares of company stock valued at $1,674,460 over the last quarter. Corporate insiders own 7.09% of the company’s stock.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Several hedge funds have recently modified their holdings of CNTA. Avoro Capital Advisors LLC boosted its holdings in Centessa Pharmaceuticals by 116.2% in the third quarter. Avoro Capital Advisors LLC now owns 10,808,080 shares of the company’s stock valued at $262,096,000 after acquiring an additional 5,808,080 shares during the last quarter. Federated Hermes Inc. acquired a new stake in Centessa Pharmaceuticals during the 3rd quarter worth approximately $42,429,000. Adage Capital Partners GP L.L.C. lifted its position in Centessa Pharmaceuticals by 20.8% during the second quarter. Adage Capital Partners GP L.L.C. now owns 8,403,000 shares of the company’s stock valued at $110,415,000 after buying an additional 1,449,000 shares in the last quarter. Balyasny Asset Management L.P. acquired a new stake in shares of Centessa Pharmaceuticals in the second quarter worth $16,052,000. Finally, Commodore Capital LP lifted its holdings in shares of Centessa Pharmaceuticals by 39.3% during the 2nd quarter. Commodore Capital LP now owns 3,298,289 shares of the company’s stock valued at $43,340,000 after acquiring an additional 930,711 shares in the last quarter. 82.01% of the stock is owned by institutional investors and hedge funds.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.